TY  - JOUR
AU  - Basset, Marco
AU  - Kimmich, Christoph R
AU  - Schreck, Nicholas
AU  - Krzykalla, Julia
AU  - Dittrich, Tobias
AU  - Veelken, Kaya
AU  - Goldschmidt, Hartmut
AU  - Seckinger, Anja
AU  - Hose, Dirk
AU  - Jauch, Anna
AU  - Müller-Tidow, Carsten
AU  - Benner, Axel
AU  - Hegenbart, Ute
AU  - Schönland, Stefan O
TI  - Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
JO  - British journal of haematology
VL  - 195
IS  - 2
SN  - 1365-2141
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell
M1  - DKFZ-2021-01748
SP  - 230-243
PY  - 2021
N1  - 2021 Oct;195(2):230-243
AB  - Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL. Patients received a median of two prior treatment lines (68
KW  - AL amyloidosis (Other)
KW  - biomarkers (Other)
KW  - gain 1q21 (Other)
KW  - lenalidomide (Other)
KW  - prognosis (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34341985
DO  - DOI:10.1111/bjh.17685
UR  - https://inrepo02.dkfz.de/record/170085
ER  -